Showing results (911-920 of 1,095) with videos related to

Sort By:
Pageof 110
Scientific Reports|August 26, 2018
RNAm expression profile of cancer marker genes in HepG2 cells treated with different concentrations of a new indolin-3-one from Pseudomonas aeruginosaLucas Milanez Benicio, Ane Stefano Simionato, Cláudio Roberto Novello, et al.
BMJ Open|January 12, 2026
Telehealth-delivered exercise and nutrition intervention to improve outcomes in patients with early stage non-small cell lung cancer: protocol for the multicentre STARLighT phase II (neoadjuvant) and phase III (adjuvant) trialAlice Avancini, Diana Giannarelli, Stefano Ugel, et al.
Cell Death & Disease|November 11, 2020
Pharmacological antagonism of kainate receptor rescues dysfunction and loss of dopamine neurons in a mouse model of human parkin-induced toxicityMaria Regoni, Stefano Cattaneo, Daniela Mercatelli, et al.
Cancer Treatment Reviews|December 19, 2012
Second Italian consensus conference on malignant pleural mesothelioma: state of the art and recommendationsCarmine Pinto, Silvia Novello, Valter Torri, et al.
European Journal of Cancer (Oxford, England : 1990)|April 18, 2025
Correlation between irAEs and survival outcomes in patients with ES-SCLC treated with first-line chemoimmunotherapyFederico Monaca, Igor Gomez-Randulfe, Ana Sofia Parreira, et al.
JTO Clinical and Research Reports|November 24, 2025
Crizotinib in Patients With <i>ROS1</i>-Positive NSCLC With or Without Brain Metastases: Post Hoc Analysis of Phase II METROS TrialLorenza Landi, Rita Chiari, Marcello Tiseo, et al.
Cancers|April 27, 2024
Predictors of Survival, Treatment Modalities, and Clinical Outcomes of Diffuse Large B-Cell Lymphoma in Patients Older Than 70 Years Still an Unmet Medical Need in 2024 Based on Real-World EvidenceLuís Alberto de Pádua Covas Lage, Rita Novello De Vita, Lucas Bassolli de Oliveira Alves, et al.
Oncoimmunology|February 6, 2018
Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environmentChiara Riganti, Marcello Francesco Lingua, Iris Chiara Salaroglio, et al.
Therapeutic Advances in Chronic Disease|July 31, 2020
GNS561 acts as a potent anti-fibrotic and pro-fibrolytic agent in liver fibrosis through TGF-β1 inhibitionEloïne Bestion, Zuzana Macek Jilkova, Jean-Louis Mège, et al.
Future Oncology (London, England)|November 5, 2020
Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated <i>RET</i> positive non-small-cell lung cancerBenjamin J Solomon, Cai Cun Zhou, Alexander Drilon, et al.
Pageof 110